Impact of Home Patient Telemonitoring on Use of Î²-Blockers in Congestive Heart Failure
- Î²-Blockers in Heart Failure: The ‘New Wave’ of Clinical Trials. Krum, H. // Drugs;Aug1999, Vol. 58 Issue 2, p203
There is now considerable clinical trial data to support the use of Î²-blockers in patients with congestive heart failure (CHF) due to systolic left ventricular dysfunction. A substantial database has accumulated over the last 20 years supporting the benefits of these agents on ventricular...
- A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly. // BMC Medical Research Methodology;2011, Vol. 11 Issue 1, p106
The article presents a self-controlled case study on the use of beta blockers in improving the treatment outcomes of patients suffering from heart failure and their role in reducing hospitalization of patients. It is mentioned that the database of the Department of Veterans' Affair of Australia...
- Putting a block on heart failure deaths. Ahmed, Mohammed // GP: General Practitioner;6/3/2002, p70
Focuses on the benefits of beta-blockers in treating heart failure. Improvement of left ventricular functions; Performance of clinical trials on the effects of carvedilol; Reduction of mortality.
- Two beta blockers: two difference effects on CHF. // Medical Marketing & Media;Jul2001, Vol. 36 Issue 7, p26
Examines the effects of beta blockers on chronic heart failure. Reduction on the risk of death; Decrease of hospitalization costs; Distributor of bucindol drugs.
- Treatment of chronic heart failure with Î² adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Maggioni, A.P.; Sinagra, G.; Opasich, C.; Geraci, E.; Gorini, M.; Gronda, E.; Lucci, D.; Tognoni, G.; Balli, E.; Tavazzi, L. // Heart;Mar2003, Vol. 89 Issue 3, p299
Background: Several large controlled trials have shown that Î² blockers given to patients with heart failure (New York Heart Association functional class II-IV) reduce morbidity and mortality. Despite these impressive results, implementing the use of Î² blockade in clinical practice appears...
- Obstacles to the initiation of Î² blockers for heart failure in a specialised clinic within a district general hospital. Mahmoudi, M.; McDonagh, S.; Poole-Wilson, P.A.; Dubrey, S.W. // Heart;Apr2003, Vol. 89 Issue 4, p442
Examines the obstacles to the initiation of beta blockers for heart failure in a specialized clinic within a district general hospital. Data showing that beta blocker therapy should be used regardless of age, presence of diabetes, renal impairment or concomitant therapy with digitalis,...
- Beta-Blocker Therapy for Chronic Heart Failure. Carter, Chuck // American Family Physician;4/15/2003, Vol. 67 Issue 8, p1793
Discusses the study 'Î’-Blockers in Chronic Heart Failure: Considerations for Selecting an Agent,' by M.L. Kukin, from the November 2002 issue of the journal 'Mayo Clinic Proceedings.'
- Survival of patients aged >70 years on beta blockers. // Age & Ageing;Sep2009, Vol. 38 Issue 5, p501
The article reports on the results of a trial of 272 patients over the age of 70 years with heart failure who were either treated or left untreated with a beta-blocking agent.
- Are we oversubscribing Ã¢ blockers for heart disease? // BMJ: British Medical Journal;10/6/2012, Vol. 345 Issue 7877, p13
The article reports a study in the October 2012 issue of "The Journal of the American Medical Association," which found that the use of Î² blockers is not as useful as once believed for cardiovascular risk except for heart failure or as secondary prevention after a recent myocardial infarction...